Abstract
e14664 Background: Standard of care in the treatment of stage III colorectal cancer (CRC) involves 6 months of adjuvant combination chemotherapy with 5-FU and oxaliplatin. Despite lack of true comparative study, 2 regimens FOLFOX (MOSAIC trial) and CAPOX (XELOXA trial) are believed to be similar in their efficacy and tolerability. However, the latter has been disputed as real-life data presented from Canada has shown CAPOX to be more toxic, leading to more frequent rate of reduction in its dose intensity. Consequently, its impact on clinical outcomes has been brought to question. Methods: A retrospective data review was conducted by Segal Cancer Centre (SCC) Quebec, and Tom Baker Cancer Centre (TBCC) Alberta, on patients with stage III CRC between 2006-2013. Patients were treated with either CAPOX or mFOLFOX6 as per Canadian treatment guidelines. Primary endpoints were dose intensity and toxicity with secondary endpoints disease free survival (DFS) and overall survival (OS). Results: 180 patients (80 SCC,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
